{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:40:51Z","timestamp":1777725651704,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10147-024-02581-5","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:03:48Z","timestamp":1721754228000},"page":"1435-1443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6422-4033","authenticated-orcid":false,"given":"Ryutaro","family":"Onaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2581_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA et al (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33:27\u201363","journal-title":"Endocr Pathol"},{"key":"2581_CR2","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1089\/thy.2009.0110","volume":"19","author":"DS Cooper","year":"2009","unstructured":"Cooper DS et al (2009) Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167\u20131214","journal-title":"Thyroid"},{"key":"2581_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1\u2013133","journal-title":"Thyroid"},{"key":"2581_CR4","unstructured":"National comprehensive cancer network clinical practice guidelines in oncology, Thyroid Carcinoma, version 2.2024"},{"key":"2581_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621\u2013630","journal-title":"N Engl J Med"},{"key":"2581_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet 384:319\u2013328","journal-title":"The Lancet"},{"key":"2581_CR7","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.21873\/invivo.12350","volume":"35","author":"Y Ito","year":"2021","unstructured":"Ito Y, Onoda N, Kudo T et al (2021) Sorafenib and lenvatinib treatment for metastasis\/recurrence of radioactive iodine-refractory differentiated thyroid carcinoma. In Vivo 35:1057\u20131064","journal-title":"In Vivo"},{"key":"2581_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/thy.2022.0054","volume":"33","author":"M Kim","year":"2023","unstructured":"Kim M, Jin M, Jeon MJ et al (2023) Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study. Thyroid 33:91\u201399","journal-title":"Thyroid"},{"key":"2581_CR9","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/cas.12826","volume":"106","author":"N Kiyota","year":"2015","unstructured":"Kiyota N, Schlumberger M, Muro K et al (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106:1714\u20131721","journal-title":"Cancer Sci"},{"key":"2581_CR10","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1210\/jc.2015-3989","volume":"101","author":"B Robinson","year":"2016","unstructured":"Robinson B, Schlumberger M, Wirth LJ et al (2016) Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 101:4103\u20134109","journal-title":"J Clin Endocrinol Metab"},{"key":"2581_CR11","doi-asserted-by":"publisher","first-page":"1139659","DOI":"10.3389\/fonc.2023.1139659","volume":"13","author":"C Matsuyama","year":"2023","unstructured":"Matsuyama C, Enokida T, Ueda Y et al (2023) Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 13:1139659","journal-title":"Front Oncol"},{"key":"2581_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","volume":"106","author":"M Tahara","year":"2019","unstructured":"Tahara M, Brose MS, Wirth LJ et al (2019) Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 106:61\u201368","journal-title":"Eur J Cancer"},{"key":"2581_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000359","volume":"3","author":"M Tahara","year":"2018","unstructured":"Tahara M (2018) Management of recurrent or metastatic thyroid cancer. ESMO Open 3:e000359","journal-title":"ESMO Open"},{"key":"2581_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","volume":"33","author":"S Filetti","year":"2022","unstructured":"Filetti S, Durante C, Hartl DM et al (2022) ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 33:674\u2013684","journal-title":"Ann Oncol"},{"key":"2581_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1210\/clinem\/dgab731","volume":"107","author":"MS Brose","year":"2022","unstructured":"Brose MS, Panaseykin Y, Konda B et al (2022) A randomized study of lenvatinib 18 mg vs 24\u00a0mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 107:776\u2013787","journal-title":"J Clin Endocrinol Metab"},{"key":"2581_CR16","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1111\/cas.15465","volume":"113","author":"K Ohno","year":"2022","unstructured":"Ohno K, Shibata T, Ito KI (2022) Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Sci 113:3193\u20133210","journal-title":"Cancer Sci"},{"key":"2581_CR17","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.clgc.2016.08.014","volume":"15","author":"MC Ornstein","year":"2017","unstructured":"Ornstein MC, Wood L, Elson P et al (2017) Clinical effect of dose escalation after disease progression in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 15:e275\u2013e280","journal-title":"Clin Genitourin Cancer"},{"key":"2581_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12020-022-03117-5","volume":"78","author":"C Masaki","year":"2022","unstructured":"Masaki C, Sugino K, Akaishi J et al (2022) Successful dose escalation of lenvatinib for thyroid cancer after disease progression. Endocrine 78:77\u201384","journal-title":"Endocrine"},{"key":"2581_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676\u2013690","journal-title":"Cell"},{"key":"2581_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40801-022-00346-y","volume":"10","author":"C Masaki","year":"2023","unstructured":"Masaki C, Sugino K, Tanizawa Y et al (2023) Multikinase inhibitor treatment patterns for advanced thyroid cancer in japan: an administrative claims database study. Drugs Real World Outcomes 10:145\u2013158","journal-title":"Drugs Real World Outcomes"},{"key":"2581_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s11523-022-00926-6","volume":"17","author":"M Mohammadi","year":"2022","unstructured":"Mohammadi M, Jansen-Werkhoven TM, Ijzerman NS et al (2022) Dutch gastrointestinal stromal tumor (GIST) Registry data comparing sunitinib with imatinib dose escalation in second-line advanced non-KIT exon 9 mutated GIST patients. Target Oncol 17:627\u2013634","journal-title":"Target Oncol"},{"key":"2581_CR22","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/cncr.34493","volume":"128","author":"MS Brose","year":"2022","unstructured":"Brose MS, Robinson BG, Sherman SI et al (2022) Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial. Cancer 128:4203\u20134212","journal-title":"Cancer"},{"key":"2581_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","volume":"173","author":"T Higashiyama","year":"2022","unstructured":"Higashiyama T, Sugino K, Hara H et al (2022) Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer 173:210\u2013218","journal-title":"Eur J Cancer"},{"key":"2581_CR24","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.anl.2018.05.003","volume":"45","author":"H Goto","year":"2018","unstructured":"Goto H, Kiyota N, Otsuki N et al (2018) Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria. Auris Nasus Larynx 45:1249\u20131252","journal-title":"Auris Nasus Larynx"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02581-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02581-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02581-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T17:06:19Z","timestamp":1727111179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02581-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2581"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02581-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Dr. Tahara reports grants and personal fees from Ono Pharmaceutical and Bayer; and personal fees from MSD, BMS, Merck Biopharma, Pfizer, Rakuten Medical, Lilly, Boehringer Ingelheim, Eisai, Chugai Pharmaceutical, Daiichi-Sankyo, Janssen Pharmaceutical, Genmab, Astra Zeneca, Abbvie and Astellas outside the submitted work. Dr. Enokida reports personal fees from Ono Pharmaceutical, Bayer, MSD, and Merck Biopharma outside the submitted work. Dr. Okano reports personal fees from Ono Pharmaceutical, MSD, BMS, and Merck Biopharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}